精神分裂症患者利培酮治疗停药后的血脂水平变化

doi:10.3969/j.issn.1671-7171.2016.10.021

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1232 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the changes of serum lipids in schizophrenic patients after withdrawal of risperidone treatment.【Methods】 Ninety-three cases of schizophrenia in our hospital were divided into 3 groups, 33 patients (group A) were not treated with antipsychotic drugs, 31 patients (group B) were treated with antipsychotic drugs, and 30 patients ceased antipsychotic treatment the risperidone for at least 3 months or more (group C). In addition, 32 healthy volunteers were selected as normal control group (group D).【Results】 The general clinical data and demographic data of all the patients were collected, and levels of body weight, waist and hip circumference, fasting serum three triglycerides (TG), total cholesterol (TC), high density lipoprotein (HDL-C), low density lipoprotein cholesterol (LDL-C), apolipoprotein A1 (apoA₁) and apolipoprotein A2 (apoA₂) were measured. BMI of the Group C was significantly higher than that of the Group A, the difference was statistically significant (P<0.05); The serum HDL level of the Group B and the Group C was significantly lower than that of A group, and the difference was statistically significant (P<0.05).【Conclusion】 The withdrawal of risperidone treatment in schizophrenic patients can not reverse the abnormal serum lipids in the short term.

Key words： Schizophrenia/DT Isoxazoles/TU Piperidines/TU Lipids/BL

Received: 25 March 2016

PACS:

R749.3

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CAI Li-li
	LI Li-qun
	LI Yang
	et al

Cite this article:

CAI Li-li,LI Li-qun,LI Yang, et al. Changes of Serum Lipids in Schizophrenic Patients after Withdrawal of Risperidone Treatment[J]. JOURNAL OF CLINICAL RESEARCH, 2016, 33(10): 1935-1937.

URL:

http://www.jcr.net.cn/EN/10.3969/j.issn.1671-7171.2016.10.021 OR http://www.jcr.net.cn/EN/Y2016/V33/I10/1935

[1] Shan D,Lucas EK,Drummond JB,et al.Abnormal expression of glutamate transporters in temporal lobe areas in elderly patients with schizophrenia[J].Schizophr Res,2013,144(1-3):1-8.
[2] FontaineKR, HeoM, Harrigan EP, et al. Estimating the consequences of anti-psychotic induced weight gain on health andmortality rate[J].Psychiatry Res,2001, 101(3): 277-288.
[3] 王继辉,魏钦令,李冠英,等.稳定期精神分裂症患者体力活动水平及体力活动咨询调查[J].中华医学杂志,2015,95(15)1140-1143.
[4] Wirshing DA. Schizophrenia and obesity:impact of antipsychotic medications[J].J Clin Psychiatry,2004,65(Suppl18):13-26.
[5] 云跃,陈黎明,范林钰.不同抗精神病药物对精神分裂症患者临床疗效和糖脂代谢的影响[J].西部医学,2015,27(6):843-846.
[6] 李洁,姚贵忠,刘丽娟,等.非典型抗精神病药物相关代谢不良反应的系统评价和 meta-分析[J].中国心理卫生杂志,2015,29(3):210-216.
[7] 叶志远.阿立哌唑和利培酮治疗精神分裂症的有效性和安全性比较[J].中国医药,2014,9(4):553-556.
[8] 辛一帆,李光梅.齐拉西酮与利培酮治疗女性精神分裂症的对照研究[J].西部医学,2013,25(8):1215-1217.
[9] 王海华,姚琳,潘丽红. 奥氮平合并齐拉西酮及行为干预对精神分裂症患者体质量和糖脂代谢的影响[J].临床精神医学杂志,2016,26(1):44-46.
[10] 梅力,易正辉.精神分裂症伴发代谢综合征的防治研究进展[J].中国神经精神疾病杂志,2014,40(7):443-446.
[11] 陈登国,刘家胜.齐拉西酮与氯丙嗪对精神分裂症患者代谢综合征影响[J].医学临床研究,2013,30(2):280-281.
[12] 傅正闯,张鹏.帕利哌酮与利培酮治疗精神分裂症的安全性对照研究[J].中国医药导报,2014,11(9):101-103.
[13] 吴小立,秦峰,王继辉,等.精神分裂症患者血脂代谢异常情况及停用抗精神病药物的影响[J].中华神经医学杂志,2015,14(2):156-161.
[14] 陈青,万敏,班春霞,等.上海流浪精神分裂症患者心血管危险因素患病率的回顾性评估[J].上海精神医学,2014,26(3):149-156.

[1]	. [J]. JOURNAL OF CLINICAL RESEARCH, 2016, 33(10): 2066-2068.